Compare IPI & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPI | CCCC |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 358.6M | 240.3M |
| IPO Year | 2008 | 2020 |
| Metric | IPI | CCCC |
|---|---|---|
| Price | $27.50 | $2.57 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $23.00 | $8.50 |
| AVG Volume (30 Days) | 120.7K | ★ 1.4M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $222,728,000.00 | $30,108,000.00 |
| Revenue This Year | $23.99 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.93 | N/A |
| 52 Week Low | $20.86 | $1.09 |
| 52 Week High | $39.01 | $4.89 |
| Indicator | IPI | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 61.83 | 50.39 |
| Support Level | $25.04 | $2.50 |
| Resistance Level | $26.51 | $2.84 |
| Average True Range (ATR) | 0.93 | 0.18 |
| MACD | 0.29 | -0.00 |
| Stochastic Oscillator | 85.91 | 45.44 |
Intrepid Potash Inc produces and sells potash and potash byproducts in three main product segments: Potash, Trio, and Oilfield Solutions. The Potash segment produces and sells potash to the agricultural industry as a fertilizer input, the industrial market as a component of oil and gas drilling fluid, and the animal feed market as a nutrient supplement. The Trio segment produces and sells specialty fertilizer that consists of potassium, sulfate, and magnesium and is mined from langbeinite ore. The oilfield solutions segment offers water, high-speed potassium chloride mixing services, saltwater disposal services, and trucking services. The vast majority of revenue is generated in the United States, which is also the location of the firm's production facilities.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.